EAM
CGON icon

Eventide Asset Management’s CG Oncology CGON Stock Holding History

Eventide Asset Management’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.3M Sell
369,839
-146
-0% -$9.54K 0.35% 93
2026
Q1 		$25M Buy
369,985
+57,540
+18% +$3.26M 0.41% 87
2025
Q4 		$13M Buy
+312,445
New +$12.9M 0.2% 129

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Eventide Asset Management's CGON Position: Q2 2026 in Review

Eventide Asset Management reduced its CG Oncology (CGON) stake by 0.04% in Q2 2026, selling an estimated $9.54K and leaving 369,839 shares worth $26.3M. The position accounts for 0.35% of the portfolio, ranked #93.

Eventide Asset Management first reported a position in CGON in Q4 2025 and has held it in 3 quarters since. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • Eventide Asset Management held 369,839 shares of CG Oncology worth $26.3M as of Q2 2026.
  • Eventide Asset Management sold 146 CG Oncology shares in Q2 2026, an estimated $9.54K.
  • CG Oncology made up 0.35% of Eventide Asset Management's portfolio in Q2 2026, its #93 holding.
  • Eventide Asset Management first reported a position in CG Oncology in Q4 2025 and has held it in 3 quarters since.
  • 227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Eventide Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.